Precision early cancer screening
Detect cancer before symptoms appear!
Precise probe-based early screening using digital PCR technology for the most commonly present mutations and genes in almost all cancer types. The test in non-invasive and uses the extracted cell free DNA from the serum/plasma of the patient. It allows for an early detection of genetic anomalies in the patient's blood, which might indicated the risk of presence of cancer cells.
- Non-invasive and reliable early cancer detection
- Results in just 5-10 business days
- Ultra-sensitive digital PCR technology with 99.99% accuracy
Know sooner. Act smarter. Live healthier.
A simple, non-invasive blood test that analyzes cell-free DNA (cfDNA) using digital PCR (ddPCR) to detect early genetic changes linked to multiple cancer types. Supports early prevention and personalized treatment planning.
Next-Generation Biotech Innovations
Why we do the cancer cfDNA surveillance with our dqPCR technology
In the realm of oncology, early detection and continuous monitoring of cancer are critical for successful treatment outcomes. Our advanced detection platform leverages circulating free DNA (cfDNA) as biomarkers, offering a significant leap over traditional cancer detection methods.
Traditional cancer diagnostics often rely on imaging and tissue biopsies, which have limitations in sensitivity, especially for detecting early-stage disease or monitoring for minimal residual disease post-treatment. In contrast, our technology employs digital PCR (dpPCR) to detect cfDNA with unparalleled precision. The dpPCR amplifies and quantifies specific DNA sequences, allowing for the detection of rare genetic material that is characteristic of cancer cells, even at very low levels, at really early stage of cancer occurs or lower cancer cells exsit.
The graph we present visualizes this advantage: even in the post-treatment, doctors sign the patient as " Cancer free", cfDNA levels plummet, suggesting a reduction in tumor burden. Yet, the sensitivity of dpPCR can reveal subtle increases in cfDNA, potentially flagging early signs of cancer recurrence well before traditional methods would identify them. This enhanced sensitivity is pivotal not only for early detection but also for monitoring patients during the so-called 'cancer-free' intervals. Our dpPCR technology can therefore provide a more accurate reflection of the patient’s disease status.
By integrating our dpPCR-based cfDNA surveillance into early cancer screening and clinical practice, we offer oncologists a powerful tool for real-time, non-invasive tumor tracking. This technological advancement stands to transform patient care by enabling earlier therapeutic intervention and more informed clinical decision-making.
more and more cancer genes cf-DNA can be detected
Associated cancers as shown here
